Perrigo Company plc (NYSE:PRGO – Get Free Report) CFO Eduardo Guarita Bezerra purchased 3,000 shares of the company’s stock in a transaction on Monday, August 18th. The shares were purchased at an average cost of $22.74 per share, for a total transaction of $68,220.00. Following the completion of the transaction, the chief financial officer directly owned 48,949 shares of the company’s stock, valued at approximately $1,113,100.26. This represents a 6.53% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Perrigo Price Performance
Shares of PRGO opened at $23.6850 on Thursday. The firm has a market capitalization of $3.26 billion, a PE ratio of -40.84 and a beta of 0.47. The company’s 50-day moving average is $26.20 and its 200-day moving average is $26.24. Perrigo Company plc has a fifty-two week low of $21.03 and a fifty-two week high of $30.93. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.32 and a quick ratio of 1.24.
Perrigo (NYSE:PRGO – Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.59 by ($0.02). The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.08 billion. Perrigo had a negative net margin of 1.86% and a positive return on equity of 9.09%. Perrigo’s revenue for the quarter was down .9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.53 earnings per share. Equities analysts forecast that Perrigo Company plc will post 2.56 EPS for the current year.
Perrigo Dividend Announcement
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on PRGO shares. JPMorgan Chase & Co. dropped their price objective on shares of Perrigo from $38.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. Canaccord Genuity Group lowered their price target on shares of Perrigo from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Finally, Wall Street Zen raised shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, August 16th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $33.00.
View Our Latest Analysis on Perrigo
Institutional Investors Weigh In On Perrigo
A number of large investors have recently bought and sold shares of PRGO. Price T Rowe Associates Inc. MD grew its stake in Perrigo by 6,828.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,845,539 shares of the company’s stock worth $201,710,000 after buying an additional 7,732,309 shares in the last quarter. Millennium Management LLC grew its stake in Perrigo by 5,198.0% during the first quarter. Millennium Management LLC now owns 2,052,599 shares of the company’s stock worth $57,555,000 after buying an additional 2,013,856 shares in the last quarter. Norges Bank acquired a new stake in Perrigo during the second quarter worth about $36,755,000. Ion Asset Management Ltd. grew its stake in Perrigo by 34.7% during the second quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock worth $102,007,000 after buying an additional 983,727 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Perrigo by 126.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after buying an additional 647,982 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Stories
- Five stocks we like better than Perrigo
- 3 Small Caps With Big Return Potential
- Lowe’s Builds Value for Investors: Still a Good Buy in 2025
- How to trade penny stocks: A step-by-step guide
- Jackson Hole 2025: Fed’s Signal Could Shift Stocks Fast
- How to Most Effectively Use the MarketBeat Earnings Screener
- Rocket Lab Stock: Breakout Brewing or Time for Patience?
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.